KQB548 / Kumquat Biosci, Bayer - LARVOL DELTA

Bayer and Kumquat Biosciences Enter Global Exclusive License and Collaboration in Precision Oncology (Businesswire) - "Under the agreement, Kumquat is responsible for the initiation and completion of the Phase Ia study, while Bayer will complete development and commercial activities. Kumquat received U.S. Food and Drug Administration (FDA) clearance of the investigational new drug (IND) for its KRAS G12D inhibitor in July 2025. Under the terms of the agreement, Kumquat will receive up to $1.3 billion..."

IND • Licensing / partnership • Colorectal Cancer • Non Small Cell Lung Cancer • Pancreatic Cancer